• AMMAR ALMAAYTAH Faculty of Pharmacy, Middle East University, Amman, Jordan, Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan



Trastuzumab, Biosimilars, Similarity, Biological comparability, Guidance


The introduction of monoclonal antibodies (mAbs) into the field of oncology has revolutionized the treatment options available to clinicians for the treatment of several malignancies. Unlike their classical small molecule drug counterparts, mAbs are large complex biological molecules that are generated using recombinant engineering and produced through the use of living systems. The high complexity of these agents, combined with the complexity of their manufacturing process, poses significant challenges for the pharmaceutical industry in producing exact copies of the originator molecules. With several mAbs losing their patency in recent years, several pharmaceutical manufacturers are pursuing the development of mAb copies or what is known as biosimilars as generic copies to the originator mAbs. Developing a mAb biosimilar requires that the manufacturer performs an extensive comparability exercise between the originator mAb and its biosimilar to provide evidence that the biological copy is similar to the originator in regards to physicochemical and functional properties, non-clinical pharmacodynamics and immunogenicity, and finally, clinical trials to ensure the safety and efficacy of the biological molecule. The inability to perform a high-quality similarity exercise could generate inferior biological copies or what is known as intended copies. Trastuzumab is a humanized mAb that was designed to target HER 2 receptors which are highly expressed in a variety of tumors, including 25-30% of invasive breast carcinomas. The aim of this review is to provide technical guidance regarding the physicochemical and functional similarity exercise for pharmaceutical personnel working in the research and development of Trastuzumab biosimilars in addition to regulatory officer’s worldwide reviewing biosimilars dossiers within public health authorities. This data will provide valuable information in detailing the main quality parameters needed to demonstrate the analytical similarity of any Trastuzumab biosimilar to its reference product.


Download data is not yet available.


Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005;54(1):11-29. doi: 10.1016/j.critrevonc.2004.10.011.

Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer. 2019;121(3):199-210. doi: 10.1038/s41416-019-0480-z.

Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA A Cancer Journal for Clinicians. 2013;63(4):249-79. doi: 10.3322/caac.21184.

Kumar A. Comprehensive review on etiopathogenesis, treatment and emerging therapies of breast cancer. Asian J Pharm Clin Res. 2021:20-33. doi: 10.22159/ajpcr.2021.v14i8.41974.

Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/Neu-overexpressing breast cancer: A systematic review. Cancer Treat Rev. 2008;34(6):539-57. doi: 10.1016/j.ctrv.2008.03.013.

Oostra DR, Macrae ER. Role of trastuzumab Emtansine in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2014;6:103-13. doi: 10.2147/BCTT.S67297, PMID 25114588.

Kumar NM, Sivadas A, RL. Trastuzumab-induced respiratory distress: A case report. Asian J Pharm Clin Res. 2018;11(10):1. doi: 10.22159/ajpcr.2018.v11i10.24343.

Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/Neu-overexpressing cells. Nat Cell Biol. 2001;3(3):245-52. doi: 10.1038/35060032.

Maadi H, Nami B, Tong J, Li G, Wang Z. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer. 2018;18(1). doi: 10.1186/s12885-018-4143-x.

Arteaga C, Moulder S, Yakes F. HER (erbb) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol. 2002;29(3):4-10. doi: 10.1016/S0093-7754(02)70121-8.

Browne B, O’Brien N, Duffy M, Crown J, O’Donovan N. Her-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets. 2009;9(3):419-38. doi: 10.2174/156800909788166484.

Hudis CA. Trastuzumab- mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51. doi: 10.1056/NEJMra043186.

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by her2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92-8. doi: 10.1200/JCO.2008.19.9844.

Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies. Drugs. 2011;71(12):1527-36. doi: 10.2165/11593730-000000000-00000.

Declerck PJ. BioLogicals and Biosimilars: a review of the science and its implications. Generics and Biosimilars Initiative Journal. 2012;1(1):13-6.

Temel DB, Landsman P, Brader ML. Orthogonal methods for characterizing the unfolding of therapeutic monoclonal antibodies: Differential scanning calorimetry, isothermal chemical denaturation, and intrinsic fluorescence with concomitant static light scattering. Methods Enzymol. 2016;567:359-89. doi: 10.1016/bs.mie.2015.08.029, PMID 26794361.

Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34(4):393-400. doi: 10.1038/nbt.3525.

Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6). doi: 10.1002/prp2.535.

Ahuja NK, Rajawat JS. Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights. Int J App Pharm. 2021:31-40. doi: 10.22159/ijap.2021v13i6.42912.

Beck A. Biosimilar, Biobetter and next-generation therapeutic antibodies. mAbs. 2011;3(2):107-10. doi: 10.4161/mabs.3.2.14785.

Chow SC, Wang J, Endrenyi L, Lachenbruch PA. Scientific considerations for assessing biosimilar products. Statist Med. 2013;32(3):370-81. doi: 10.1002/sim.5571.

Declerck PJ. Biosimilar monoclonal antibodies: A science-based regulatory challenge. Expert Opin Biol Ther. 2013;13(2):153-6. doi: 10.1517/14712598.2012.758710.

Cornes P, Aapro M. The impact of biosimilars in supportive care in cancer. Eur Oncol Haematol. 2018;14(1):20. doi: 10.17925/EOH.2018.14.1.20.

Castaneda Hernandez G, Gonzalez Ramirez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: what the clinician should know. RMD Open. 2015;1(1):e000010. doi: 10.1136/rmdopen-2014-000010.

Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36(5):613-25. doi: 10.1007/s00296-016-3444-0.

Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: A multidisciplinary perspective. Clin Ther. 2016;38(5):1238-49. doi: 10.1016/j.clinthera.2016.02.023.

Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the Healthcare Community. BioDrugs. 2017;31(3):175-87. doi: 10.1007/s40259-017-0218-5.

Lopez Morales CA, Miranda Hernandez MP, Juarez Bayardo LC, Ramirez Ibanez ND, Romero Diaz AJ, Pina Lara N. Physicochemical and biological characterization of a biosimilar trastuzumab. BioMed Res Int. 2015;2015:427235. doi: 10.1155/2015/427235, PMID 26075238.

Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe. mAbs. 2013;5(5):621-3. doi: 10.4161/mabs.25864.

Flad T, Chumsae C. Primary structure and peptide mapping. Monoclonal Antibodies. 2021:93-119.

Hada V, Bagdi A, Bihari Z, Timari SB, Fizil A, Szantay C. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of Protein biotherapeutics: A viewpoint from the biosimilar industry. J Pharm Biomed Anal. 2018;161:214-38. doi: 10.1016/j.jpba.2018.08.024.

Li W, Kerwin JL, Schiel J, Formolo T, Davis D, Mahan A. Structural elucidation of post-translational modifications in monoclonal antibodies. ACS Symp S. 2015:119-83. doi: 10.1021/bk-2015-1201.ch003.

Bennett KL, Smith SV, Truscott RJW, Sheil MM. Monitoring papain digestion of a monoclonal antibody by electrospray ionization mass spectrometry. Anal Biochem. 1997;245(1):17-27. doi: 10.1006/abio.1996.9904.

Wang S, Ionescu R, Peekhaus N. Leung Jyu, Ha S, Vlasak J. Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. J Chromatogr A. 2010;42:6496-502.

Gokarn Y, Agarwal S, Arthur K, Bepperling A, Day ES, Filoti D. Biophysical techniques for characterizing the higher order structure and interactions of monoclonal antibodies. ACS Symp S. 2015:285-327. doi: 10.1021/bk-2015-1201.ch006.

Lin JC, Glover ZK, Sreedhara A. Assessing the utility of circular dichroism and FTIR spectroscopy in monoclonal-antibody comparability studies. J Pharm Sci. 2015;104(12):4459-66. doi: 10.1002/jps.24683.

Wen J, Batabyal D, Knutson N, Lord H, Wikstrom M. A comparison between emerging and current biophysical methods for the assessment of higher-order structure of biopharmaceuticals. J Pharm Sci. 2020;109(1):247-53. doi: 10.1016/j.xphs.2019.10.026.

Garidel P, Hegyi M, Bassarab S, Weichel M. A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol J. 2008;3:1201-11. doi: 10.1002/biot.200800091.

Molina P, Schick AJ, Welch L, Niedringhaus T, Hierro Gd, Deperalta G. Using differential scanning calorimetry for the development of non-reduced capillary electrophoresis sodium dodecyl sulfate methods for monoclonal antibodies. Anal Biochem. 2020;609:113948. doi: 10.1016/j.ab.2020.113948.

Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology. 2017;56(Suppl 4):14-29. doi: 10.1093/rheumatology/kex278.

Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol. 2021;41(2):300-15. doi: 10.1080/07388551.2020.1869684, PMID 33430641.

Büttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals. 2011;39(2):100-9. doi: 10.1016/j.biologicals.2011.01.006.

Sanchez De Melo I, Grassi P, Ochoa F, Bolivar J, Garcia Cozar FJ, Duran Ruiz MC. N-glycosylation profile analysis of trastuzumab biosimilar candidates by normal phase liquid chromatography and MALDI-TOF MS approaches. J Proteomics. 2015;127:225-33. doi: 10.1016/j.jprot.2015.04.012.

Kaji H, Yamauchi Y, Takahashi N, Isobe T. Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site–specific stable isotope tagging. Nat Protoc. 2006;1(6):3019-27. doi: 10.1038/nprot.2006.444.

Duivelshof BL, Jiskoot W, Beck A, Veuthey JL, Guillarme D, D’Atri V. Glycosylation of biosimilars: recent advances in analytical characterization and clinical implications. Anal Chim Acta. 2019;1089:1-18. doi: 10.1016/j.aca.2019.08.044.

Gupta S, Jiskoot W, Schoneich C, Rathore AS. Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and efficacy. J Pharm Sci. 2022;111(4):903-18. doi: 10.1016/j.xphs.2021.11.024, PMID 34890632.

Trivedi M, Laurence J, Siahaan T. The role of thiols and disulfides on protein stability. Curr Protein Pept Sci. 2009;10(6):614-25. doi: 10.2174/138920309789630534.

Beck A, Liu H. Macro-and micro-heterogeneity of natural and recombinant IGG antibodies. Antibodies. 2019;8(1):18. doi: 10.3390/antib8010018.

Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol. 2008;9(6):468-81. doi: 10.2174/138920108786786402, PMID 19075686.

Zhao YY, Wang N, Liu WH, Tao WJ, Liu LL, Shen ZD. Charge variants of an avastin biosimilar isolation, characterization, in vitro properties and pharmacokinetics in rat. Plos One. 2016;11(3):e0151874. doi: 10.1371/journal.pone.0151874, PMID 26987122.

Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X. Charge variants in IgG1. mAbs. 2010;2(6):613-24. doi: 10.4161/mabs.2.6.13333.

Ratih R, Asmari M, Abdel Megied AM, Elbarbry F, El Deeb S. Biosimilars: review of regulatory, manufacturing, analytical aspects and beyond. Microchem J. 2021;165:106143. doi: 10.1016/j.microc.2021.106143.

Bedard P, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted her-2 therapy in breast cancer. Curr Cancer Drug Targets. 2009;9(2):148-62. doi: 10.2174/156800909787581024.

Jeong SA, Choi JM, Park JM, Lee JY, Lee SJ, Lee SY. Mechanism of action of the trastuzumab biosimilar CT-P6. Expert Opin Biol Ther. 2019;19(10):1085-95. doi: 10.1080/14712598.2019.1554052.

Jassem S, Wang W, Sweet H, Manoukian R, Chow V, Kanakaraj P. Functional and nonclinical similarity of ABP 980, a biosimilar of trastuzumab. Pharm Res. 2019;36(12). doi: 10.1007/s11095-019-2702-8.

Joshi S, Rathore AS. Assessment of structural and functional comparability of biosimilar products: trastuzumab as a case study. BioDrugs. 2020;34(2):209-23. doi: 10.1007/s40259-020-00404-3.



How to Cite




Review Article(s)